X4 Pharmaceuticals, Inc (XFOR)
Data as of , from SEC Form 4 filings.
Net insider selling (90d)Watch XFOR
See up to 3 months of XFOR. The 7-day demo opens the 1M and 3M ranges and puts XFOR on your watchlist.
Start 7-day demoLatest XFOR insider trades
- David Kirske - OfficerOpen-market sale$34K
John Volpone - OfficerOpen-market sale$109K
About X4 Pharmaceuticals, Inc (XFOR)
X4 Pharmaceuticals, Inc is an SEC registrant, filing under CIK 0001501697, classified as biological products (no diagnostic substances). We track it alongside the rest of the Health Care sector.
XFOR Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 3 | 83,779 | $354K |
XFOR insider transactions (Form 4)
3423 Form 4 filings on record, the earliest from Oct 8, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| David Kirske - Officer | Open-market sale | Common Stock | 11,767 | $2.86 footnote F2 | $34K | |
| ||||||
| John Volpone - Officer | Open-market sale | Common Stock | 24,576 | $4.44 footnote F2 | $109K | |
| ||||||
| Adam R. Craig - Officer | Open-market sale | Common Stock | 47,436 | $4.44 footnote F2 | $211K | |
| ||||||
| David Kirske - Officer | Open-market sale | Common Stock | 8,543 | $4.26 footnote F2 | $36K | |
| ||||||
| Kelly Gold - Director | Grant or award | Stock Option (right to buy) | 110,000 | $0.00 | - | |
| David Kirske - Officer | Open-market sale | Common Stock | 16,961 | $4.29 footnote F2 | $73K | |
| ||||||
| John Volpone - Officer | Grant or award | Stock Option (right to buy) | 2,329,154 | $0.00 | - | |
| Adam R. Craig - Officer | Grant or award | Stock Option (right to buy) | 2,329,154 | $0.00 | - | |
| David Kirske - Officer | Grant or award | Stock Option (right to buy) | 1,552,769 | $0.00 | - | |
| Adam R. Craig - Officer | Open-market purchase | Common Stock | 86,206 footnote F1 | $2.90 | $250K | |
| ||||||
| John Volpone - Officer | Grant or award | Common Stock | 289,881 | $0.00 | - | |
| John Volpone - Officer | Grant or award | Stock Option (right to buy) | 1,609,873 | $0.00 | - | |
| John Volpone - Officer | Grant or award | Stock Option (right to buy) | 529,201 | $0.00 | - | |
| Adam R. Craig - Officer | Grant or award | Common Stock | 289,881 | $0.00 | - | |
| Adam R. Craig - Officer | Grant or award | Stock Option (right to buy) | 1,609,873 | $0.00 | - | |
| Adam R. Craig - Officer | Grant or award | Stock Option (right to buy) | 529,201 | $0.00 | - | |
| David Kirske - Officer | Grant or award | Common Stock | 193,254 | $0.00 | - | |
| David Kirske - Officer | Grant or award | Stock Option (right to buy) | 1,073,249 | $0.00 | - | |
| David Kirske - Officer | Grant or award | Stock Option (right to buy) | 352,800 | $0.00 | - | |
| David W. J. McGirr - Director | Grant or award | Common Stock | 1,500 | $0.00 | - | |
| Michael S. Wyzga - Director | Grant or award | Common Stock | 1,500 | $0.00 | - | |
 Natasha Fay Thoren - Officer | Grant or award | Common Stock | 3,333 | $0.00 | - | |
| Paula Ragan - Officer | Open-market sale | Common Stock | 31,897 | $0.39 | $13K | |
| Paula Ragan - Officer | Open-market sale | Common Stock | 31,897 | $0.56 | $18K | |
| Adam S. Mostafa - Officer | Grant or award | Common Stock | 230,645 | $0.00 | - | |
| Adam S. Mostafa - Officer | Open-market sale | Common Stock | 230,645 | $0.55 | $127K | |
| Mark Baldry - Officer | Grant or award | Common Stock | 34,946 | $0.00 | - | |
| Mark Baldry - Officer | Open-market sale | Common Stock | 11,127 | $0.58 | $7K | |
| Paula Ragan - Officer | Grant or award | Common Stock | 532,081 | $0.00 | - | |
| Paula Ragan - Officer | Open-market sale | Common Stock | 239,436 | $0.55 | $132K | |
| Mary Dibiase - Officer | Grant or award | Common Stock | 230,645 | $0.00 | - | |
| Mary Dibiase - Officer | Open-market sale | Common Stock | 67,695 | $0.57 | $38K | |
| Arthur Taveras - Officer | Grant or award | Common Stock | 230,645 | $0.00 | - | |
| Arthur Taveras - Officer | Open-market sale | Common Stock | 76,920 | $0.56 | $43K | |
Item 1.01, 1.02, 2.03, 3.02, 7.01, 9.01
Item 8.01, 9.01
Item 8.01, 9.01
Item 5.02, 7.01, 9.01
Recent XFOR Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| David Kirske | Officer | 11,767 | $34K | View on EDGAR | |
| John Volpone | Officer | 24,576 |
XFOR insider trading FAQ
What is the latest insider trade for XFOR?
X4 Pharmaceuticals, Inc (XFOR) had 3 insider filings in the last 90 days, with the most recent on 2026-10-05. The full record for XFOR runs to 23 Form 4 filings, the earliest from 2024-10-08. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying XFOR stock?
No insider purchases of XFOR were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling XFOR stock?
3 insider sales of XFOR were filed in the last 90 days, totaling $354K.
Where can I see XFOR SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects XFOR Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - David Kirske view on EDGAR
- - John Volpone view on EDGAR
- - Adam R. Craig view on EDGAR
- - David Kirske view on EDGAR
- - Kelly Gold view on EDGAR
- - David Kirske view on EDGAR
- - John Volpone view on EDGAR
- - Adam R. Craig view on EDGAR
- - David Kirske view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where XFOR's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow XFOR with a 7-day demo
- XFOR on your watchlist
- Every XFOR Form 4 filing on record
- Up to 3 months of XFOR price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
